Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AURKA shRNA lentiviral transduction
- Development stage
- Preclinical
- Lead developer
- National Institute of Neurological Disorders and Stroke
- Modality
- Viral-delivered RNAi → In Vivo RNAi → Gene Silencing → Gene Therapies
- Administration
- Intratumoral
01
Overview
AURKA shRNA lentiviral transduction is an experimental gene therapy approach used to downregulate the expression of Aurora Kinase A (AURKA). In the context of glioblastoma research, this method involves using a lentiviral vector to deliver short hairpin RNA (shRNA) that specifically targets and degrades AURKA mRNA via the RNA interference (RNAi) pathway. AURKA is a key component of the ciliary disassembly complex; its inhibition or knockdown leads to the stabilization and increased abundance of primary cilia. Research suggests that restoring primary cilia in glioblastoma cells can significantly alter the cellular transcriptome, potentially suppressing multiple pro-cancer and immunosuppressive pathways. This approach is currently being explored as a ciliotherapeutic strategy to address the genetic complexity and immune evasion characteristic of malignant primary brain tumors.
- Other names
- AURKA knockdownAURKA shRNA
02
Targets
AURKA (Aurora kinase A)
Beyond the preview
Go deeper on AURKA shRNA lentiviral transduction.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AURKA shRNA lentiviral transduction.